MET and breast carcinoma: Results revealed a significant and dose-responsive inhibition of HGF-induced c-Met phosphorylation after treatment with HVS for 72 h in the three used c-Met-dependent breast cancer cell lines, as compared to their respective vehicle-treated control groups, consistent with the in vitro kinase activity of HVS.